New FDA approval: Tymlos (abaloparatide) for Osteoporosis

New FDA approval: Tymlos (abaloparatide) for Osteoporosis

In April 2017, FDA approved Tymlos/AbaloParatide for treatment of postmenopausal osteoporosis. Tymlos has potent bone anabolic properties (PTH1 receptors). It is administered once a day subcutaneously for up to 2 years. Side effect could be nausea and palpitations. The original study published in JAMA June 2016 suggests overall tymlos superiority over forteo in fracture reduction and bone density improvement during an 18 month observation.

GT

Read more →

要查看或添加评论,请登录

Gerti Tashko, MD的更多文章

社区洞察

其他会员也浏览了